A plain language summary of the SAVANNAH study: savolitinib plus osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification whose cancer had grown or spread on osimertinib.
de Marinis F, Kim TM, Bonanno L, Cheng S, Kim SW, Tiseo M, Chu Q, Proto C, Sacher A, Luo YH, Novello S, Hao D, Baik C, Bazhenova L, Lee JS, Cho BC, Cadranel J, Diep TB, Metro G, Narayanan P, Yoneshima Y, de Castro Carpeño J, Baldotto C, Yang JC, Sequist LV, Levy B, Hartmaier R, Igwegbe I, Poole L, Xu W, Ahn MJ.
de Marinis F, et al. Among authors: yang jc.
Future Oncol. 2026 Jul 16:1-13. doi: 10.1080/14796694.2026.2692029. Online ahead of print.
Future Oncol. 2026.
PMID: 42460617